Syndromе associated with multiple venous malformations (Bean syndrome)
- Authors: Hachatryan L.A.1, Kletskaya I.S.1, Orekhova E.V.1
- 
							Affiliations: 
							- Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
 
- Issue: Vol 18, No 3 (2019)
- Pages: 78-87
- Section: CLINICAL OBSERVATIONS
- Submitted: 13.09.2019
- Accepted: 13.09.2019
- Published: 13.09.2019
- URL: https://hemoncim.com/jour/article/view/264
- DOI: https://doi.org/10.24287/1726-1708-2019-18-3-78-87
- ID: 264
Cite item
Full Text
Abstract
Blue rubber bleb nevus syndrome (BRBNS) also called Bean's syndrome is a rare disorder characterized by mucocutaneous angiomatose multiple cutaneous venous malformations. Pathogenesis of the BRBNS is caused by the somatic mutations in angiopoietin receptor gene TEK. These mutations cause ligand-independent activation of the tyrosine kinase receptor and the PI3K / AKT pathway and involve the mTOR in the pathological process in a specific way. There are no universally effective methods for treating systemic forms of vascular malformations currently. However, recent numerous reports have shown the advantages of rapamycin, an mTOR inhibitor, as a well-tolerated and effective therapy in patients with vascular abnormalities, in particular with diffuse angiomatose. This article presents a clinical case of a 5-years old patient with a diagnosis of iron deficiency anemia, who has been treated for a long time and received iron supplements therapy without achieving any effect. The diagnosis of Bean's syndrome was established after 5 years from the first clinical manifestation and based on clinical, laboratory and instrumental methods. The cause of iron deficiency anemia was established. It was repeated chronic bleedings from multiple sites of the gastrointestinal mucosa vessels. Prescribed rapamycin therapy allowed to contain gastrointestinal bleeding, to reduce the size of vascular lesions and to prevent the formation of new ones. Parents gave their consent to use information about the child in the article.
About the authors
L. A. Hachatryan
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
							Author for correspondence.
							Email: Lili.2510@yandex.ru
				                	ORCID iD: 0000-0001-7265-0414
				                																			                								
Lili A. Hachatryan, MD, hematologist, Head of Box Department of Hematology/ Oncology
117997, Moscow, Samory Mashela st., 1
Russian FederationI. S. Kletskaya
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
																		                	ORCID iD: 0000-0002-8552-7682
				                																			                								Moscow				                	Russian Federation													
E. V. Orekhova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationMoscow Russian Federation
References
Supplementary files
 
				
			 
					 
						 
									
 
  
  
  Email this article
			Email this article 

